Willingness to pay for mortality risk reductions: does latency matter?
From MaRDI portal
(Redirected from Publication:867448)
Recommendations
- Effects of disease type and latency on the value of mortality risk
- Social willingness to pay, mortality risks and contingent valuation
- Cancer premiums and latency effects: A risk tradeoff approach for valuing reductions in fatal cancer risks
- Does risk aversion increase the value of mortality risk?
- To be, or not to be, that is the question: An empirical study of the WTP for an increased life expectancy at an advanced age
Cites work
- Age, health and the willingness to pay for mortality risk reductions: A contingent valuation survey of Ontario residents
- On the value of changes in life expectancy: Blips versus parametric changes
- The value of a statistical life: A critical review of market estimates throughout the world
- To be, or not to be, that is the question: An empirical study of the WTP for an increased life expectancy at an advanced age
Cited in
(8)- Estimating willingness to pay for Medicare using a dynamic life-cycle model of demand for health insurance
- Social willingness to pay, mortality risks and contingent valuation
- Effects of risk and time preference and expected longevity on demand for medical tests
- On consumer preferences and the willingness to pay for term life insurance
- How Much Does the Far Future Matter? A Hierarchical Bayesian Analysis of the Public's Willingness to Mitigate Ecological Impacts of Climate Change
- Does risk aversion increase the value of mortality risk?
- Effects of disease type and latency on the value of mortality risk
- Cancer premiums and latency effects: A risk tradeoff approach for valuing reductions in fatal cancer risks
This page was built for publication: Willingness to pay for mortality risk reductions: does latency matter?
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q867448)
